Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | CD69 | Q07108 | 1/20 | 0.43 |
| ▸ | HRAS | P01112 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16489969 | 0.93 | SLC6A2 (0.43) | SLC6A2HRASPOLBLGALS3 | |
| SCHEMBL15975418 | 0.88 | TP53 (0.45) | CD69HRASPOLBLGALS3 | |
| SCHEMBL13130034 | 0.86 | POLB (0.44) | CD69HRASPOLBLGALS3 | |
| SCHEMBL16489965 | 0.84 | L3MBTL1 (0.38) | SLC6A2LGALS3 | |
| SCHEMBL16489960 | 0.84 | MAG (0.42) | SLC6A2HRASLGALS3 | |
| SCHEMBL16489958 | 0.82 | LGALS8 (0.40) | SLC6A2HRASPOLBLGALS3 | |
| SCHEMBL11170198 | 0.81 | MAG (0.49) | CD69HRASPOLBLGALS3 | |
| SCHEMBL11494535 | 0.81 | MAG (0.49) | CD69HRASPOLBLGALS3 | |
| SCHEMBL11170193 | 0.81 | MAG (0.49) | CD69HRASPOLBLGALS3 | |
| SCHEMBL15975417 | 0.81 | GJB2 (0.41) | SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150050282-A1 | GLYCOCONJUGATES AND USE THEREOF AS VACCINE AGAINST SHIGELLA FLEXNERI SEROTYPE 3a AND X | INSTITUT PASTEUR (FR) | 2015-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150050282-A1 | GLYCOCONJUGATES AND USE THEREOF AS VACCINE AGAINST SHIGELLA FLEXNERI SEROTYPE 3a AND X | ST3GAL3, SI, STT3A | SLC6A2 2998/4885CD69 127/4885HRAS 3755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.